CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

- Continued progress with lead program, CX-2051 (EpCAM PROBODY^® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 -